Towards clinical applications of selected reaction monitoring for plasma protein biomarker studies

Proteomics - Clinical Applications

Volumn 6, Issue 1-2, 2012, Pages 42-59

  Krisp, Christoph ^a,b   Randall, Sarah A ^a   McKay, Matthew J ^a   Molloy, Mark P ^a  

^a MACQUARIE UNIVERSITY   (Australia)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Biomarker; Plasma; Protein; Quantitation; Selected reaction monitoring

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLUSTERIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN 4 PROTEIN; K RAS PROTEIN; MESOTHELIN; PROSTATE SPECIFIC ANTIGEN; PYRUVATE KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER; UNCLASSIFIED DRUG; VITRONECTIN;

ACCURACY; BIOLOGICAL MONITORING; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DOWN SYNDROME; GENETIC DISORDER; HUMAN; METABOLIC DISORDER; NEOPLASM; NERVE DEGENERATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; REPRODUCIBILITY; REVIEW; SELECTED REACTION MONITORING; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; BLOOD PROTEINS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DOWN SYNDROME; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES;

EID: 84858980337     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100062     Document Type: Review

References (165)

1. Ashley, E. A., Butte, A. J., Wheeler, M. T., Chen, R. et al., Clinical assessment incorporating a personal genome. Lancet 2010, 375, 1525-1535.
2. Jabbour, E., Cortes, J. E., Ghanem, H., O'Brien, S.,Kantarjian, H. M., Targeted therapy in chronic myeloidleukemia. Expert Rev. Anticancer 2008, 8, 99-110.
3. An, X., Tiwari, A. K., Sun, Y., Ding, P.-R. et al., BCR-ABLtyrosine kinase inhibitors in the treatment of Philadelphiachromosome positive chronic myeloid leukemia: a review. Leukemia Res. 2010, 34, 1255-1268.
4. Eng, C., The evolving role of monoclonal antibodies incolorectal cancer: early presumptions and impact on clinicaltrial development. Oncologist 2010, 15, 73-84.
5. Tol, J., Punt, C. J. A., Monoclonal antibodies in the treatmentof metastatic colorectal cancer: a review. Clin. Ther.2010, 32, 437-453.
6. Wang, Q., Chaerkady, R., Wu, J., Hwang, H. J. et al., Mutantproteins as cancer-specific biomarkers. Proc. Natl. Acad. Sci. USA 2011, 108, 2444-2449.
7. Fu, Q., Schoenhoff, F. S., Savage, W. J., Zhang, P., Van Eyk,J. E., Multiplex assays for biomarker research and clinicalapplication: translational science coming of age. ProteomicsClin. Appl. 2010, 4, 271-284.
8. Crowther, J. R., The ELISA Guidebook, 2nd Edn, HumanaPress, New Jersey 2009.
9. Gallien, S., Duriez, E., Domon, B., Selected reactionmonitoring applied to proteomics. J. Mass Spectrom.2011, 46, 298-312.
10. Huttenhain, R., Malmstrom, J., Picotti, P., Aebersold, R.,Perspectives of targeted mass spectrometry for proteinbiomarker verification. Curr. Opin. Chem. Biol. 2009, 13,518-525.
11. Domon, B., Aebersold, R., Mass spectrometry and proteinanalysis. Science 2006, 312, 212-217.
12. Han, B., Higgs, R. E., Proteomics: From hypothesis toquantitative assay on a single platform. Guidelines fordeveloping MRM assays using ion trap mass spectrometers. Brief. Funct. Genomic. Proteomic. 2008, 7,340-354.
13. Prakash, A., Tomazela, D. M., Frewen, B., MacLean, B. et al., Expediting the development of targeted SRM assays:using data from shotgun proteomics to automate methoddevelopment. J. Proteome Res. 2009, 8, 2733-2739. Proteomics Clin. Appl. 2012, 6, 42-59.
14. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selectedreaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 1-14.
15. Anderson, L., Hunter, C. L., Quantitative mass spectrometricmultiple reaction monitoring assays for majorplasma proteins. Mol. Cell. Proteomics 2006, 5, 573-588.
16. Kuhn, E., Addona, T., Keshishian, H., Burgess, M. et al.,Developing multiplexed assays for Troponin I and Interleukin-33 in plasma by peptide immunoaffinity enrichmentand targeted mass spectrometry. Clin. Chem. 2009, 55,1108-1117.
17. Whiteaker, J. R., Zhao, L., Abbatiello, S. E., Burgess, M. et al., Evaluation of large scale quantitative proteomic assaydevelopment using peptide affinity-based mass spectrometry. Mol. Cell. Proteomics 2011, 10, M110.005645.
18. Whiteaker, J. R., Zhao, L., Anderson, L., Paulovich, A. G.,An automated and multiplexed method for high throughputpeptide immunoaffinity enrichment and multiplereaction monitoring mass spectrometry-based quantificationof protein biomarkers. Mol. Cell. Proteomics 2010, 9,184-196.
19. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J. et al., Multiplereaction monitoring-based, multiplexed, absolute quantitationof 45 proteins in human plasma. Mol. Cell. Proteomics2009, 8, 1860-1877.
20. Makawita, S., Diamandis, E. P., The bottleneck in thecancer biomarker pipeline and protein quantificationthrough mass spectrometry-based approaches: currentstrategies for candidate verification. Clin. Chem. 2010, 56,212-222.
21. U.S. Food and Drug Administration: Centre for DrugEvaluation and Research, Guidance for industry: BioanalyticalMethod Validation, 2011. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
22. Anderson, N. L., Anderson, N. G., The human plasmaproteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
23. Anderson, N. L., Anderson, N. G., The human plasmaproteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2003, 2, 50.
24. Surinova, S., Schiess, R., H. uttenhain, R., Cerciello, F. et al.,On the development of plasma protein biomarkers.J. Proteome Res. 2011, 10, 5-16.
25. Anderson, N. L., The clinical plasma proteome: A survey ofclinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56, 177-185.
26. Polanski, M., Anderson, N. L., A list of candidate cancerbiomarkers for targeted proteomics. Biomarker Insights2007, 1, 1-48.
27. Liao, H., Wu, J., Kuhn, E., Chin, W. et al., Use of massspectrometry to identify protein biomarkers of diseaseseverity in the synovial fluid and serum of patients withrheumatoid arthritis. Arthritis Rheum. 2004, 50, 3792-3803.
28. Kuhn, E., Wu, J., Karl, J., Liao, H. et al., Quantification ofC-reactive protein in the serum of patients with rheumatoidarthritis using multiple reaction monitoring massspectrometry and C-labeled peptide standards. Proteomics2004, 4, 1175-1186.
29. Barnidge, D. R., Goodmanson, M. K., Klee, G. G., Muddiman,D. C., Absolute quantification of the model biomarkerprostate-specific antigen in serum by LC-MS/MS usingprotein cleavage and isotope dilution mass spectrometry.J. Proteome Res. 2004, 3, 644-652.
30. Ackermann, B. L., Berna, M. J., Coupling immunoaffinitytechniques with MS for quantitative analysis of lowabundanceprotein biomarkers. Expert Rev. Proteomics2007, 4, 175-186.
31. Chiu, C.-L., Randall, S., Molloy, M. P., Recent progress inselected reaction monitoring MS-driven plasma proteinbiomarker analysis. Bioanalysis 2009, 1, 847-855.
32. Nomura, H., Fujimoto, N., Seiki, M., Mai, M., Okada, Y.,Enhanced production of matrix metalloproteinasesand activation of matrix metalloproteinase 2 (gelatinaseA) in human gastric carcinomas. Int. J. Cancer 1996, 69,9-16.
33. Mimori, K., Mori, M., Shiraishi, T., Fujie, T. et al., Clinicalsignificance of tissue inhibitor of metalloproteinaseexpression in gastric carcinoma. Br. J. Cancer 1997, 76,531-536.
34. McCarthy, K., Maguire, T., McGreal, G., McDermott, E. et al., High levels of tissue inhibitor of metalloproteinase-1predict poor outcome in patients with breast cancer. Int.J. Cancer 1999, 84, 44-48.
35. Fong, K. M., Kida, Y., Zimmerman, P. V., Smith, P. J.,TIMP1 and adverse prognosis in non-small cell lungcancer. Clin. Cancer Res. 1996, 2, 1369-1372.
36. Kallakury, B. V. S., Karikehalli, S., Haholu, A., Sheehan,C. E. et al., Increased expression of matrix metalloproteinases2 and 9 and tissue inhibitors of metalloproteinases 1and 2 correlate with poor prognostic variables in renal cellcarcinoma. Clin. Cancer Res. 2001, 7, 3113-3119.
37. Gong, Y. L., Xu, G. M., Huang, W. D., Chen, L. B., Expressionof matrix metalloproteinases and the tissue inhibitorsof metalloproteinases and their local invasiveness andmetastasis in Chinese human pancreatic cancer. J. Surg. Oncol. 2000, 73, 95-99.
38. Aldulaymi, B., Bystrom, P., Berglund, A., Christensen, I. J. et al., High plasma TIMP-1 and serum CEA levels duringcombination chemotherapy for metastatic colorectalcancer are significantly associated with poor outcome. Oncology 2010, 79, 144-149.
39. Inagaki, D., Oshima, T., Yoshihara, K., Tamura, S. et al.,Overexpression of tissue inhibitor of metalloproteinase-1gene correlates with poor outcomes in colorectal cancer. Anticancer Res. 2010, 30, 4127-4130.
40. Wang, C.-S., Wu, T.-L., Tsao, K.-C., Sun, C.-F., SerumTIMP-1 in gastric cancer patients: a potential prognosticbiomarker. Ann. Clin. Lab. Sci. 2006, 36, 23-30.
41. Anderson, N. L., Anderson, N. G., Haines, L. R., Hardie,D. B. et al., Mass spectrometric quantitation of peptidesand proteins using stable isotope standards and captureby anti-peptide antibodies (SISCAPA). J. Proteome Res.2004, 3, 235-244.
42. Ahn, Y. H., Lee, J. Y., Lee, J. Y., Kim, Y.-S. et al., Quantitativeanalysis of an aberrant glycoform of TIMP1 fromcolon cancer serum by L-PHA-enrichment and SISCAPAwith MRM mass spectrometry. J. Proteome Res. 2009, 8,4216-4224.
43. Lilja, H., Ulmert, D., Vickers, A. J., Prostate-specific antigenand prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 2008, 8, 268-278.
44. Bul, M., J. van Leeuwen, P., Zhu, X., Schroder, F. H., J. Roobol, M., Prostate cancer incidence and disease-specificsurvival of men with initial prostate-specific antigen lessthan 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur. Urol. 2011, 59, 498-505.
45. Payne, H., Cornford, P., Prostate-specific antigen: Anevolving role in diagnosis, monitoring, and treatmentevaluation in prostate cancer. Urol. Oncol. - Semin. Ori.2011, 29, 593-601.
46. Fortin, T., Salvador, A., Charrier, J. P., Lenz, C. et al.,Clinical quantitation of prostate-specific antigen biomarkerin the low nanogram/milliliter range by conventional boreliquid chromatography-tandem mass spectrometry(multiple reaction monitoring) coupling and correlationwith ELISA tests. Mol. Cell. Proteomics 2009, 8, 1006-1015.
47. Fortin, T., Salvador, A., Charrier, J. P., Lenz, C. et al.,Multiple reaction monitoring cubed for protein quantificationat the low nanogram/milliliter level in nondepletedhuman serum. Anal. Chem. 2009, 81, 9343-9352.
48. Windgassen, E. B., Funtowicz, L., Lunsford, T. N., Harris,L. A., Mulvagh, S. L., C-Reactive protein and high-sensitivityc-reactive protein: an update for clinicians. Postgrad. Med. 2011, 123.
49. Emerging Risk Factors Collaboration, Kaptoge, S., DiAngelantonio, E., Lowe, G. et al., C-reactive proteinconcentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375, 132-140.
50. Amos, R. S., Constable, T. J., Crockson, R. A., Crockson,A. P., McConkey, B., Rheumatoid arthritis: relation ofserum C-reactive protein and erythrocyte sedimentationrates to radiographic changes. Br. Med. J. 1977, 1, 195-197.
51. Spector, T. D., Hart, D. J., Nandra, D., Doyle, D. V. et al.,Low-level increases in serum C-reactive protein arepresent in early osteoarthritis of the knee andpredict progressive disease. Arthritis Rheum. 1997, 40,723-727.
52. Cho, D. S., Kim, S. J., Lee, S. H., Ahn, H. S. et al., Prognosticsignificance of preoperative c-reactive proteinelevation and thrombocytosis in patients with non-metastaticrenal cell carcinoma. Korean J. Urol. 2011, 52,104-109.
53. McSorley, M. A., Alberg, A. J., Allen, D. S., Allen, N. E. et al., C-Reactive protein concentrations and subsequentovarian cancer risk. Obstet. Gynecol. 2007, 109, 933-941.
54. Lundin, E., Dossus, L., Clendenen, T., Krogh, V. et al.,C-Reactive protein and ovarian cancer: a prospective studynested in three cohorts (Sweden, USA, Italy). CancerCauses Control 2009, 20, 1151-1159.
55. Williams, D. K., Muddiman, D. C., Absolute quantificationof C-reactive protein in human plasma derived frompatients with epithelial ovarian cancer utilizing proteincleavage isotope dilution mass spectrometry. J. ProteomeRes. 2009, 8, 1085-1090.
56. Kranenburg, O., The KRAS oncogene: Past, present, andfuture. BBA - Rev. Cancer 2005, 1756, 81-82.
57. Lievre, A., Bachet, J.-B., Le Corre, D., Boige, V. et al., KRASmutation status is predictive of response to cetuximabtherapy in colorectal cancer. Cancer Res. 2006, 66,3992-3995.
58. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S. et al., Activating mutations in the epidermal growthfactor receptor underlying responsiveness of non-smallcelllung cancer to gefitinib. N. Engl. J. Med. 2004, 350,2129-2139.
59. Kashyap, R. S., Nayak, A. R., Deshpande, P. S., Kabra, D. et al., Inter-alpha-trypsin inhibitor heavy chain 4 is a novelmarker of acute ischemic stroke. Clin. Chim. Acta 2009,402, 160-163.
60. Abdullah-Soheimi, S. S., Lim, B. K., Hashim, O. H., Shuib,A. S., Patients with ovarian carcinoma excrete differentaltered levels of urine CD59, kininogen-1 and fragments ofinter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci. 2010, 17, 58.
61. Canter, M. P., Graham, C. A., Heit, M. H., Blackwell, L. S. et al., Proteomic techniques identify urine proteins thatdifferentiate patients with interstitial cystitis from asymptomaticcontrol subjects. Am. J. Obstet. Gynecol. 2008,198, 553.e551-553.e556.
62. Gangadharan, B., Antrobus, R., Dwek, R. A., Zitzmann, N.,Novel serum biomarker candidates for liver fibrosis inhepatitis C patients. Clin. Chem. 2007, 53, 1792-1799.
63. Høgdall, E., Fung, E. T., Christensen, I. J., Yip, C. et al.,Proteomic biomarkers for overall and progression-freesurvival in ovarian cancer patients. Proteome Clin. Appl.2010, 4, 940-952.
64. Song, J., Patel, M., Rosenzweig, C. N., Chan-Li, Y. et al.,Quantification of fragments of human serum inter-alphatrypsininhibitor heavy chain 4 by a surface-enhanced laserdesorption/ionization-based immunoassay. Clin. Chem.2006, 52, 1045-1053.
65. Shi, Q., Harris, L. N., Lu, X., Li, X. C. et al., Declining plasmafibrinogen alpha fragment identifies HER2-positive breastcancer patients and reverts to normal levels after surgery.J. Proteome Res. 2006, 5, 2947-2955.
66. Fung, E. T., Yip, T.-T., Lomas, L., Wang, Z. et al., Classificationof cancer types by measuring variants of hostresponse proteins using SELDI serum assays. Int.J. Cancer 2005, 115, 783-789.
67. van den Broek, I., Sparidans, R. W., Schellens, J. H. M.,Beijnen, J. H., Quantitative assay for six potential breastcancer biomarker peptides in human serum by liquidchromatography coupled to tandem mass spectrometry.J. Chromatogr. B 2010, 878, 590-602.
68. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A. et al., Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006,116, 271-284.
69. van Winden, A. W. J., van den Broek, I., Gast, M.-C. W.,Engwegen, J. Y. M. N. et al., Serum degradome markersfor the detection of breast cancer. J. Proteome Res. 2010,9, 3781-3788.
70. van den Broek, I., Sparidans, R. W., van Winden, A. W. J.,Gast, M.-C. W. et al., The absolute quantification of eightinter-a-trypsin inhibitor heavy chain 4 (ITIH4)-derivedpeptides in serum from breast cancer patients. ProteomeClin. Appl. 2010, 4, 931-939.
71. van den Broek, I., Sparidans, R. W., Schellens, J. H. M.,Beijnen, J. H., Sensitive liquid chromatography/tandemmass spectrometry assay for absolute quantification ofITIH4-derived putative biomarker peptides in clinicalserum samples. Rapid Commun. Mass Spectrom. 2010, 24,1842-1850.
72. Altenberg, B., Greulich, K. O., Genes of glycolysis areubiquitously overexpressed in 24 cancer classes. Genomics2004, 84, 1014-1020.
73. Jurica, M. S., Mesecar, A., Heath, P. J., Shi, W. et al., Theallosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure 1998, 6, 195-210.
74. Mazurek, S., Boschek, C. B., Hugo, F., Eigenbrodt, E.,Pyruvate kinase type M2 and its role in tumor growth andspreading. Semin. Cancer Biol. 2005, 15, 300-308.
75. Christofk, H. R., Vander Heiden, M. G., Harris, M. H.,Ramanathan, A. et al., The M2 splice isoform of pyruvatekinase is important for cancer metabolism and tumourgrowth. Nature 2008, 452, 230-233.
76. Cerwenka, H., Aigner, R., Bacher, H., Werkgartner, G. et al.,TUM2-PK (pyruvate kinase type tumorM2),CA19-9 andCEA in patients with benign, malignant and metastasizingpancreatic lesions. Anticancer Res. 1999, 19, 849-851.
77. Luftner, D., Mesterharm, J., Akrivakis, C., Geppert, R. et al.,Tumor type M2 pyruvate kinase expression in advancedbreast cancer. Anticancer Res. 2000, 20, 5077-5082.
78. DeSouza, L. V., Taylor, A. M., Li, W., Minkoff, M. S. et al.,Multiple reaction monitoring of mTRAQ labeled peptidesenables absolute quantification of endogenous levels of apotential cancer marker in cancerous and normal endometrialtissues. J. Proteome Res. 2008, 7, 3525-3534.
79. Hardt, P. D., Mazurek, S., Toepler, M., Schlierbach, P. et al.,Faecal tumour M2 pyruvate kinase: a new, sensitivescreening tool for colorectal cancer. Br. J. Cancer 2004, 91,980-984.
80. Schulze, G., The tumor marker tumor M2-PK: An applicationin the diagnosis of gastrointestinal cancer. AnticancerRes. 2000, 20, 4961-4964.
81. Sirover, M. A., New insights into an old protein: the functionaldiversity of mammalian glyceraldehyde-3-phosphatedehydrogenase. Biochim. Biophys. Acta 1999, 1432,159-184.
82. Epner, D. E., Coffey, D. S., There are multiple forms ofglyceraldehyde-3-phosphate dehydrogenase in prostatecancer cells and normal prostate tissue. Prostate 1996, 28,372-378.
83. Revillion, F., Pawlowski, V., Hornez, L., Peyrat, J. P.,Glyceraldehyde-3-phosphate dehydrogenase geneexpression in human breast cancer. Eur. J. Cancer 2000,36, 1038-1042.
84. Zhou, Y., Yi, X., Stoffer, J. B., Bonafe, N. et al., The multifunctionalprotein glyceraldehyde-3-phosphate dehydrogenaseis both regulated and controls colonystimulating factor-1 messenger RNA stability in ovariancancer. Mol. Cancer Res. 2008, 6, 1375-1384.
85. Hassan, R., Ho, M., Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 2008, 44, 46-53.
86. Argani, P., Iacobuzio-Donahue, C., Ryu, B., Rosty, C. et al.,Mesothelin is overexpressed in the vast majority ofductal adenocarcinomas of the pancreas: identification ofa new pancreatic cancer marker by serial analysisof gene expression (SAGE). Clin. Cancer Res. 2001, 7,3862-3868.
87. Hassan, R., Kreitman, R. J., Pastan, I., Willingham, M. C.,Localization of mesothelin in epithelial ovarian cancer. Appl. Immunohistochem. Mol. Morphol. 2005, 13, 243-247.
88. Ordonez, N. G., Value of mesothelin immunostaining inthe diagnosis of mesothelioma. Mod. Pathol. 2003, 16,192-197.
89. Rump, A., Morikawa, Y., Tanaka, M., Minami, S. et al.,Binding of ovarian cancer antigen CA125/MUC16 tomesothelin mediates cell adhesion. J. Biol. Chem. 2004,279, 9190-9198.
90. Elschenbroich, S., Ignatchenko, V., Clarke, B., Kalloger,S. E. et al., In-depth proteomics of ovarian cancer ascites:combining shotgun proteomics and selected reactionmonitoring mass spectrometry. J. Proteome Res. 2011, 10,2286-2299.
91. Preissner, K. T., Seiffert, D., Role of vitronectin and itsreceptors in haemostasis and vascular remodeling. Thromb. Res. 1998, 89, 1-21.
92. Ekmekc-i, O. B., Ekmekc-i, H., Vitronectin in atheroscleroticdisease. Clin. Chim. Acta 2006, 368, 77-83.
93. Hurt, E. M., Chan, K., Duhagon Serrat, M. A., Thomas, S. B. et al., Identification of vitronectin as an extrinsic inducer ofcancer stem cell differentiation and tumor formation. StemCells 2010, 28, 390-398.
94. Derer, W., Barnathan, E. S., Safak, E., Agarwal, P. et al.,Vitronectin concentrations predict risk in patients undergoingcoronary stenting. Circ. Cardiovasc. Interv. 2009, 2,14-19.
95. Inuzuka, S., Ueno, T. K. T., Fibrogenesis in acute liverinjuries. Pathol. Res. Pract. 1994, 190, 903-909.
96. Høga° sen, K., Homann, C., Mollnes, T., Graudal, N. et al.,Serum clusterin and vitronectin in alcoholic cirrhosis. Liver1996, 16, 140-146.
97. Paradis, V., Degos, F., Dargere, D., Pham, N. et al., Identificationof a new marker of hepatocellular carcinoma byserum protein profiling of patients with chronic liverdiseases. Hepatology 2005, 41, 40-47.
98. Redondo, M., Rodrigo, I., Alcaide, J., Tellez, T. et al.,Clusterin expression is associated with decreased disease-free survival of patients with colorectal carcinomas. Histopathology 2010, 56, 932-936.
99. Redondo, M., Villar, E., Torres-Munoz, J., Tellez, T. et al.,Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 2000, 157, 393-399.
100. Pucci, S., Bonanno, E., Pichiorri, F., Angeloni, C., Spagnoli,L. G., Modulation of different clusterin isoforms inhuman colon tumorigenesis. Oncogene 2004, 23,2298-2304.
101. Hoofnagle, A. N., Wu, M., Gosmanova, A. K., Becker, J. O. et al., Low clusterin levels in high-density lipoprotein associatewith insulin resistance, obesity, and dyslipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 2528-2534.
102. Schrijvers, E. M. C., Koudstaal, P. J., Hofman, A., Breteler,M. M. B., Plasma clusterin and the risk of Alzheimerdisease. J. Am. Med. Assoc. 2011, 305, 1322-1326.
103. Zhao, Y., Jia, W., Sun, W., Jin, W. et al., Combination ofimproved 18O incorporation and multiple reaction monitoring:a universal strategy for absolute quantitative verificationof serum candidate biomarkers of liver cancer.J. Proteome Res. 2010, 9, 3319-3327.
104. Miyagi, M., Rao, K. C. S., Proteolytic 18O-labeling strategiesfor quantitative proteomics. Mass Spectrom. Rev.2007, 26, 121-136.
105. Høgasen, K., Eirik Mollnes, T., Tschopp, J., Harboe, M.,Quantitation of vitronectin and clusterin: Pitfalls andsolutions in enzyme immunoassays for adhesive proteins.J. Immunol. Methods 1993, 160, 107-115.
106. Ijsselstijn, L., Dekker, L. J. M., Koudstaal, P. J., Hofman, A. et al., Serum clusterin levels are not increased inpresymptomatic Alzheimer's disease. J. Proteome Res.2011, 10, 2006-2010.
107. Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A. et al., Association of plasma clusterin concentration withseverity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 2010, 67, 739-748.
108. International Diabetes Federation, Diabetes Atlas. 4th Edn, International Diabetes Federation, Brussels (Belgium)2010.
109. Green, P. S., Vaisar, T., Pennathur, S., Kulstad, J. J. et al.,Combined statin and niacin therapy remodels the highdensitylipoprotein proteome. Circulation 2008, 118,1259-1267.
110. Nguyen, T. T., Alibrahim, E., Islam, F. M. A., Klein, R. et al., Inflammatory, hemostatic, and other novel biomarkers fordiabetic retinopathy. Diabetes Care 2009, 32, 1704-1709.
111. Lim, L. S., Tai, E. S., Mitchell, P., Wang, J. J. et al.,C-Reactive protein, body mass index, and diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2010, 51, 4458-4463.
112. Sasongko, M. B., Wong, T. Y., Nguyen, T. T., Kawasaki, R. et al., Serum apolipoprotein ai and b are strongerbiomarkers of diabetic retinopathy than traditional lipids. Diabetes Care 2011, 34, 474-479.
113. Kim, T., Kim, S. J., Kim, K., Kang, U.-B. et al., Profiling ofvitreous proteomes from proliferative diabetic retinopathyand nondiabetic patients. Proteomics 2007, 7, 4203-4215.
114. Kim, K., Kim, S. J., Yu, H. G., Yu, J. et al., Verificationof biomarkers for diabetic retinopathy by multiplereaction monitoring. J. Proteome Res. 2009, 9,689-699.
115. Sherman, J., McKay, M. J., Ashman, K., Molloy, M. P.,How specific is my SRM?: the issue of precursorand product ion redundancy. Proteomics 2009, 9,1120-1123.
116. Adams 3d, J., Bodor, G., Davila-Roman, V., Delmez, J. et al., Cardiac troponin I. A marker with high specificity forcardiac injury. Circulation 1993, 88, 101-106.
117. Babuin, L., Jaffe, A. S., Troponin: the biomarker of choicefor the detection of cardiac injury. Canadian Med. Assoc.J. 2005, 173, 1191-1202.
118. Antman, E. M., Tanasijevic, M. J., Thompson, B., Schactman,M. et al., Cardiac-specific troponin i levels topredict the risk of mortality in patients with acutecoronary syndromes. N. Engl. J. Med. 1996, 335,1342-1349.
119. Mair, J., Artner-Dworzak, E., Lechleitner, P., Smidt, J. et al.,Cardiac troponin T in diagnosis of acute myocardialinfarction. Clin. Chem. 1991, 37, 845-852.
120. Wu, A. H. B., Feng, Y.-J., Moore, R., Apple, F. S. et al.,Characterization of cardiac troponin subunit release intoserum after acute myocardial infarction and comparison ofassays for troponin T and I. Clin. Chem. 1998, 44,1198-1208.
121. Brennan, M.-L., Penn, M. S., Van Lente, F., Nambi, V. et al.,Prognostic value of myeloperoxidase in patients withchest pain. N. Engl. J. Med. 2003, 349, 1595-1604.
122. Healy, A. M., Pickard, M. D., Pradhan, A. D., Wang, Y. et al.,Platelet expression profiling and clinical validation ofmyeloid-related protein-14 as a novel determinant ofcardiovascular events. Circulation 2006, 113, 2278-2284.
123. Karadag, B., Vatan, B., Hacioglu, Y., Duman, D. et al.,Serum myeloperoxidase level predicts reperfusion inpatients with myocardial infarction receiving thrombolytictherapy. Heart Vessels 2009, 24, 247-253.
124. Mocatta, T. J., Pilbrow, A. P., Cameron, V. A., Senthilmohan,R. et al., Plasma concentrations of myeloperoxidasepredict mortality after myocardial infarction. J. Am. Coll. Cardiol. 2007, 49, 1993-2000.
125. Seki, K., Sanada, S., Kudinova, A. Y., Steinhauser, M. L. et al., Interleukin-33 prevents apoptosis and improvessurvival after experimental myocardial infarction throughST2 signaling/clinical perspective. Circulation: Heart Fail.2009, 2, 684-691.
126. Niskanen, A., Saramaki, M., Schmandt, E., Myeloperoxidase(MPO) and hs-CRP as predictive factors for myocardialinfarction. Cardiology 2006, 18, 38-39.
127. Berton, G., Cordiano, R., Palmieri, R., Pianca, S. et al.,C-Reactive protein in acute myocardial infarction: associationwith heart failure. Am. Heart J. 2003, 145,1094-1101.
128. Wong, V. W., McLean, M., Boyages, S. C., Cheung, N. W.,C-Reactive protein levels following acute myocardialinfarction. Diabetes Care 2004, 27, 2971-2973.
129. Saleh, N., Svane, B., Velander, M., Nilsson, T. et al.,C-Reactive protein and myocardial infarction duringpercutaneous coronary intervention. J. Intern. Med. 2004,255, 33-39.
130. Bay, M., Kirk, V., Parner, J., Hassager, C. et al., NT-proBNP:A new diagnostic screening tool to differentiate betweenpatients with normal and reduced left ventricular systolicfunction. Heart 2003, 89, 150-154.
131. Weber, M., Hamm, C., Role of B-type natriuretic peptide(BNP) and NT-proBNP in clinical routine. Heart 2006, 92,843-849.
132. Seino, Y., Ogawa, A., Yamashita, T., Fukushima, M. et al.,Application of NT-proBNP and BNP measurements incardiac care: a more discerning marker for the detectionand evaluation of heart failure. Eur. J. Heart Fail. 2004, 6,295-300.
133. Wieczorek, S. J., Hager, D., Barry, M. B., Kearney, L. et al.,Correlation of B-type natriuretic peptide level to 6-minwalk test performnance in patients with left ventricularsystolic dysfunction. Clin. Chim. Acta 2003, 328, 87-90.
134. Januzzi, J. L., Camargo, C. A., Anwaruddin, S., Baggish,A. L. et al., The N-terminal Pro-BNP investigation ofdyspnea in the emergency department (PRIDE) study. Am.J. Cardiol. 2005, 95, 948-954.
135. Keshishian, H., Addona, T., Burgess, M., Mani, D. R. et al.,Quantification of cardiovascular biomarkers in patientplasma by targeted mass spectrometry and stable isotopedilution. Mol. Cell. Proteomics 2009, 8, 2339-2349.
136. Addona, T. A., Shi, X., Keshishian, H., Mani, D. R. et al., Apipeline that integrates the discovery and verification ofplasma protein biomarkers reveals candidate markers forcardiovascular disease. Nat. Biotechnol. 2011, 29, 635-643.
137. Lopez, M. F., Kuppusamy, R., Sarracino, D. A., Prakash, A. et al., Mass spectrometric discovery and selective reactionmonitoring (SRM) of putative protein biomarker candidatesin first trimester Trisomy 21 maternal serum.J. Proteome Res. 2010, 10, 133-142.
138. Bocconi, L., Nava, S., Fogliani, R., Nicolini, U., Trisomy 21is associated with hypercholesterolemia during intrauterinelife. Am. J. Obstet. Gynecol. 1997, 176, 540-543.
139. Pueschel, S. M., Craig, W. Y., Haddow, J. E., Lipids andlipoproteins in persons with Down's syndrome. J. Intellect. Disabil. Res. 1992, 36, 365-369.
140. Keshishian, H., Addona, T., Burgess, M., Kuhn, E., Carr,S. A., Quantitative, multiplexed assays for low abundanceproteins in plasma by targeted mass spectrometry andstable isotope dilution. Mol. Cell. Proteomics 2007, 6,2212-2229.
141. Nicol, G. R., Han, M., Kim, J., Birse, C. E. et al., Use of anImmunoaffinity-mass spectrometry-based approach forthe quantification of protein biomarkers from serumsamples of lung cancer patients. Mol. Cell. Proteomics2008, 7, 1974-1982.
142. Abbatiello, S. E., Mani, D. R., Keshishian, H., Carr, S. A.,Automated detection of inaccurate and imprecise transitionsin peptide quantification by multiple reaction monitoringmass spectrometry. Clin. Chem. 2010, 56, 291-305.
143. Reiter, L., Rinner, O., Picotti, P., Huttenhain, R. et al.,mProphet: automated data processing and statistical validationfor large-scale SRM experiments. Nat. Methods2011, 8, 430-435.
144. MacLean, B., Tomazela, D. M., Shulman, N., Chambers, M. et al., Skyline: an open source document editor for creatingand analyzing targeted proteomics experiments. Bioinformatics 2010, 26, 966-968.
145. Mead, J. A., Bianco, L., Ottone, V., Barton, C. et al.,MRMaid, the web-based tool for designing multiple reactionmonitoring (MRM) transitions. Mol. Cell. Proteomics2009, 8, 696-705.
146. Sherwood, C. A., Eastham, A., Lee, L. W., Peterson, A. et al., MaRiMba: A software application for spectral librarybasedMRM transition list assembly. J. Proteome Res.2009, 8, 4396-4405.
147. Deutsch, E. W., Lam, H., Aebersold, R., PeptideAtlas: Aresource for target selection for emerging targetedproteomics workflows. EMBO Rep. 2008, 9, 429-434.
148. Picotti, P., Lam, H., Campbell, D., Deutsch, E. W. et al., Adatabase of mass spectrometric assays for the yeastproteome. Nat. Methods 2008, 5, 913-914.
149. Prakash, A., Rezai, T., Krastins, B., Sarracino, D. et al.,Platform for establishing interlaboratory reproducibility ofselected reaction monitoring-based mass spectrometrypeptide assays. J. Proteome Res. 2010, 9, 6678-6688.
150. Ahn, Y. H., Kim, Y.-S., Ji, E. S., Lee, J. Y. et al., Comparativequantitation of aberrant glycoforms by lectin-basedglycoprotein enrichment coupled with multiple-reactionmonitoring mass spectrometry. Anal. Chem. 2010, 82,4441-4447.
151. Yocum, A. K., Khan, A. P., Zhao, R., Chinnaiyan, A. M.,Development of selected reaction monitoring-MS methodologyto measure peptide biomarkers in prostate cancer. Proteomics 2010, 10, 3506-3514.
152. Li, Y., Tian, Y., Rezai, T., Prakash, A. et al., Simultaneousanalysis of glycosylated and sialylated prostate-specificantigen revealing differential distribution of glycosylatedprostate-specific antigen isoforms in prostate cancertissues. Anal. Chem. 2010, 83, 240-245.
153. Selevsek, N., Matondo, M., Carbayo, M. S., Aebersold, R.,Domon, B., Systematic quantification of peptides/proteinsin urine using selected reaction monitoring. Proteomics2011, 11, 1135-1147.
154. Kilpatrick, E. L., Bunk, D. M., Reference measurementprocedure development for C-reactive protein in humanserum. Anal. Chem. 2009, 81, 8610-8616.
155. Drabovich, A. P., Diamandis, E. P., Combinatorial peptidelibraries facilitate development of multiple reaction monitoringassays for low-abundance proteins. J. ProteomeRes. 2010, 9, 1236-1245.
156. DeSouza, L. V., Romaschin, A. D., Colgan, T. J., Siu, K. W.M., Absolute quantification of potential cancer markers inclinical tissue homogenates using multiple reactionmonitoring on a hybrid triple quadrupole/linear ion traptandem mass spectrometer. Anal. Chem. 2009, 81,3462-3470.
157. Belov, M. E., Prasad, S., Prior, D. C., Danielson, W. F. et al.,Pulsed multiple reaction monitoring approach to enhancingsensitivity of a tandem quadrupole mass spectrometer. Anal. Chem. 2011, 83, 2162-2171.
158. Baralla, E., Nieddu, M., Boatto, G., Varoni, M. V. et al.,Quantitative assay for bradykinin in rat plasma by liquidchromatography coupled to tandem mass spectrometry.J. Pharm. Biomed. Anal. 2011, 54, 557-561.
159. Van Winden, A. W. J., Van Den Broek, I., Gast, M. C. W.,Engwegen, J. Y. M. N. et al., Serum degradome markersfor the detection of breast cancer. J. Proteome Res. 2010,9, 3781-3788.
160. Barton, C., Kay, R. G., Gentzer, W., Vitzthum, F., Pleasance,S., Development of high-throughput chemical extractiontechniques and quantitative HPLC-MS/MS (SRM) assaysfor clinically relevant plasma proteins. J. Proteome Res.2009, 9, 333-340.
161. Campbell, J., Rezai, T., Prakash, A., Krastins, B. et al.,Evaluation of absolute peptide quantitation strategiesusing selected reaction monitoring. Proteomics 2011, 11,1148-1152.
162. Agger, S. A.,Marney, L. C., Hoofnagle, A. N., Simultaneousquantification of Apolipoprotein A-I and Apolipoprotein Bby liquid-chromatography-multiple- reaction-monitoringmass spectrometry. Clin. Chem. 2010, 56, 1804-1813.
163. Berna, M., Ott, L., Engle, S., Watson, D. et al., Quantificationof NTproBNP in rat serum using immunoprecipitationand LC/MS/MS: a biomarker of drug-induced cardiachypertrophy. Anal. Chem. 2008, 80, 561-566.
164. Ang, C.-S., Nice, E. C., Targeted in-gel MRM: A hypothesisdriven approach for colorectal cancer biomarkerdiscovery in human feces. J. Proteome Res. 2010, 9,4346-4355.
165. Berna, M. J., Zhen, Y., Watson, D. E., Hale, J. E., Ackermann,B. L., Strategic use of immunoprecipitation and LC/MS/MS for trace-level protein quantification: myosin lightchain 1, a biomarker of cardiac necrosis. Anal. Chem. 2007,79, 4199-4205.